期刊文献+

鼠疫F1和V保护性抗原免疫学研究进展 被引量:2

Advancement in Immunolgy of Plague Protective Antigens F1 and V
下载PDF
导出
摘要 鼠疫是一种烈性人兽共患传染病,曾经导致历史上10多亿人死亡,目前在世界各地还均有流行。抗生素治疗一般对腺鼠疫有效,但难以治疗肺鼠疫,经常有抗生素治疗仍死亡的情况发生。灭活疫苗对肺鼠疫无效,减毒活疫苗存在毒力返强的安全隐患。F1和V亚单位疫苗在动物模型中对腺鼠疫和肺鼠疫均有效,已经用减毒沙门菌系统通过口服和鼻腔途径传递系统进行免疫研究。文章综述了鼠疫亚单位疫苗和减毒活载体疫苗抗原免疫学研究进展。 Yersinia pestis is the etiological agent of bubonic and pneumonic plague. The diseases caused over 200 milllion human death in the past. Plague still occurs throughout the world today. Antibiotic treatment of bubonic plague is usually effective, but pneumonic plague is difficult to be treated and even with antibiotic therapy death often occurs. A killed whole cell plague vaccine were used in the past, but recent studies in animals showed that this vaccine offers poor protection against pneumonic disease. A live attenuated vaccine is also available. Whilst this vaccine is effective, it retains some virulence and in most countries it is not considered to be suitable for use in humans. We reviewd works to develop improved sub-unit and live attenuated vaccines against plague. A sub-unit vaccine based on the F1 and V antigens is highly effective against both bubonic and pneumonic plague when tested in animal models of disease. This vaccine has been used to explore the utility of different intranasal and oral delivery systems, based on the Salmonella vector of sub-unit vaccine.
出处 《动物医学进展》 CSCD 2006年第2期46-48,共3页 Progress In Veterinary Medicine
关键词 鼠疫耶尔森菌 鼠疫疫苗 沙门菌疫苗栽体 Yersinia pestis Plague vaccine Salmonella vaccine vector
  • 相关文献

参考文献23

  • 1Butler T. Plague and other Yersinia infections[M]. New York: Plenum Press, 1983.
  • 2Russdl P,Eley S M,Hibbs S E,et al. A comparison of plague vaccine USP and EV76 vaccine induced protection against Yersinia pcstis in a murine model[J]. Vaccine, 1995,13:1551- 1556.
  • 3Cavanaugh El C,Elisberg B L,Llewellyn C H,et al, Plsgue immunisation V indirect evidence for the efficacy of plague vaecine[J]. J Infect Dis,1974,129,S37-40.
  • 4Andrews G P,Hcath D G,Anderson Jr G W,et al, Fraction l capsular antigen (F1) purification from Yersinia peztis CO92 and from Escherichia coli recombinant strain and efficacy against lethal plague challenge [J]. Infect Immun, 1996,64:2180-2187.
  • 5Centers for Disease Control. Plague vaccine[J]. Morb Mort Wkly Rep, 1982,31:301-304.
  • 6Williansson E D, Eley S M, Griffin K F, et al, A new improved sub-unit vacdne for plaguc z the basis of protection[J], FEMS Immunol Med Microbiol, 1995,12:223-230,
  • 7Price S B,Cowan C,Perry R D. TheYersinia pestis V antigen is a regulatory protein necessary for Ca2 + -dependent growth and maximal expression of low-Ca2 + response virulence genes[J]. J Bacteriol, 1991,173:2649-2657.
  • 8Nakaiima R, Motin V L, Brubaker R R, et aL Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunisation[J]. Infect Immure, 1995,63 : 3021-3029.
  • 9Chen T H, Meyer K F. Studies on immunisation against plague[J].Ⅶ J Immunol, 1954,72:782-298.
  • 10Leary S E C, Williamson E D, Griffin K F,et al. Active immunisation with V-antigen from Yersinia pestis protects against plague[J]. Infect Immun, 1995,63:2854-2858.

二级参考文献19

  • 1[2]Andrews GP, Heath DG, Anderson GW, et al. Fraction 1capsular antigen(F1) purification from Yersinia pestis CO92and an Escherichia coli recombinant strain and efficacy against lethal plague challenge [ J ]. Infect Immun, 1996, 64 (6):2 180-2 187.
  • 2[3]Titball RW, Howells AM, Oyston PC, et al. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of the aroA mutant of Salmonella typhimurium induces high levels of protection against plague [J]. Infect immun,1997,65(5): 1 926 - 1 930.
  • 3[4]Leary SE, Williamson ED, Griffin KF, et al. Active immunization with recombinant V antigen from Yersinia pestis protect mice against plague[J]. Infect Immunol, 1995, 63(8):2 854 - 2 858.
  • 4[5]Williamson ED, Sharp G J, Eley SM, et al. Local and system immune response to a microencapsulated sub-unit vaccine for plague[J]. Vaccine, 1996,14(17/18): 1 613- 1 619.
  • 5[6]Eyles JE,Williamson ED, Spiers ID, et al. Protection studies following bronchopulmonary and intramuscular immunization with Y. pestis F1 and V sub-unit vaccine coencapsulated in biodegradable microspheres: a comparsion of efficacy [J].Vaccine, 2000,18(28): 3 266 - 3 271.
  • 6[7]Leary SE,Griffin KF, Gannory HS, et al. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague [ J]. Microbial Pathogenesis, 1997, 23(3): 167 - 179.
  • 7[8]Health DG, Anderson JW, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine [J]. Vaccine,1998, 16 (11/12): 1 131- 1 137.
  • 8Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine, 2001, 19: 4175-4184.
  • 9Titball RW, Hill J, Lawton DG, et al. Yersinia pestis and plague. Biochem Soci Trans, 2003, 31: 101-107.
  • 10Liu MA. DNA vaccine: a review. J Internal Medicine, 2003, 253: 402-410.

共引文献12

同被引文献32

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部